N/A N=402 Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Transthyretin Familial Amyloid Polyneuropathy
Primary: Percentage of Participants With ADRs in This Study — 58; 12 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 Clinical Investigation of Wysa
Mental Health Issue · Anxiety · Depressive Symptoms
Primary: Depression Severity — 9.28; 8.41 units on a scale
Phase 4 N=36 A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Multiple Sclerosis · Fatigue · Insomnia
Primary: Change in Insomnia Severity Index (ISI) Score — -4; -2 score on a scale
N/A N=20 Head-up Tilt Test in Patients With Reflex Syncope and Asystolic Response Who Received a Dual-chamber Pacemaker With the Closed Loop Stimulation (CLS) and Participated in the BIOSync Trial
Syncope · Syncope, Vasovagal
Primary: Heart Rate [Bpm] at Specific Time-points During Head-up Tilt Test (HUTT) Examination — 70; 88; 105; 95 beats per minute
Phase 4 N=303 Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils
Obstruction · Cancer · Ileus
Primary: Prealbumin — 0.15; 0.16 g/l
Phase 4 N=120 Colchicine for the Treatment of Osteoarthritis of the Knee
Osteoarthritis · Osteo Arthritis Knee
Primary: Change in Visual Analog Scale (VAS) Pain Score — -1.45; -1.16 score on a scale
N/A N=500 Antenatal Chlamydia Trachomatis and Neisseria Gonorrhoeae Testing to Prevent Adverse Neonatal Consequences
Chlamydia Trachomatis Infection · Neonatal Infection · Preterm Birth
Primary: Number of Women Diagnosed With C. Trachomatis and N. Gonorrhoeae Infection at Post-delivery — 2; 23 Participants
N/A N=105 rTMS for MDD: 5.5cm Rule vs. F3 Targeting
Major Depressive Disorder · Depression
Primary: Percentage Change in Patient Health Questionnaire 9-Item Assessment Score — -38.7; -39.1 percentage of change from baseline — p=0.945
Phase 2 N=124 Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD
Mild Cognitive Impairment · Alzheimer Disease
Primary: Average Maximal Increment of Anti-Aβ40 Antibody Signal (Optical Density [OD] in ELISA) — 0.12; 3.27 OD — p=<0.0001
Phase 1 N=54 A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers
Healthy
Primary: SAD: Number of Subjects Reporting TEAEs and STEAEs — 0; 0; 0; 1 participants
Phase 2 N=20 Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
Aplastic Anemia
Primary: Hematologic Response Rate at 6 Months (Week 26) by Investigator — 70.0 Percentage of participants
Phase 2 N=39 Lidocaine Patches Prior to Percutaneous Nerve Evaluation
Overactive Bladder · Urge Incontinence · Fecal Incontinence
Primary: Visual Analog Scale Pain Score — 45; 61 mm
N/A N=420 Treatment of Persistent Atrial Fibrillation With Sphere-9 Catheter and Affera Mapping and Ablation System
Atrial Fibrillation
Primary: Percent of Subjects With a Primary Adverse Event — 3; 2 Participants — p=<0.0001
N/A N=30 Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Treatment Characteristics: Duration of Treatment With BLENREP — 9.3 Months
Phase 2 N=274 Efficacy and Safety Evaluation of Anti-Caries Varnish
Dental Caries in Children
Primary: Caries Increment — 9.8; 11.3 Number of tooth surfaces — p=0.279